Literature DB >> 34012149

Medicolegal aspects of teledermatology.

J Arimany-Manso1,2,3, R M Pujol4, V García-Patos5, U Saigí1, C Martin-Fumadó1,3,6.   

Abstract

Teledermatology has facilitated specialist care during the crisis caused by the coronavirus disease 2019 pandemic, eliminating unnecessary office visits and the possible exposure of patients or dermatologists. However, teledermatology brings forward certain ethical and medicolegal questions. A medical consultation in which the patient is not physically present is still a medical act, to which all the usual ethical and medicolegal considerations and consequences apply. The patient's right to autonomy and privacy, confidentiality, and data protection must be guaranteed. The patient must agree to remote consultation by giving informed consent, for which a safeguard clause should be included. Well-defined practice guidelines and uniform legislation are required to preserve the highest level of safety for transferred data. Adequate training is also needed to prevent circumstances involving what might be termed "telemalpractice."
© 2020 AEDV. Published by Elsevier España, S.L.U.

Keywords:  Clinical safety; Informed consent; Malpractice; Safeguard clause; Teledermatology; Telemedicine

Mesh:

Year:  2020        PMID: 34012149      PMCID: PMC7836632          DOI: 10.1016/j.adengl.2020.08.014

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  28 in total

Review 1.  Telemedicine and teledermatology: Past, present and future.

Authors:  Elisabeth M T Wurm; Rainer Hofmann-Wellenhof; Robert Wurm; Hans Peter Soyer
Journal:  J Dtsch Dermatol Ges       Date:  2007-11-12       Impact factor: 5.584

2.  Teledermatology: a useful tool to fight COVID-19.

Authors:  Alessia Villani; Massimiliano Scalvenzi; Gabriella Fabbrocini
Journal:  J Dermatolog Treat       Date:  2020-04-13       Impact factor: 3.359

3.  Position Statement of the Spanish Academy of Dermatology and Venereology on Teledermatology.

Authors:  D Moreno-Ramírez; G Romero-Aguilera; P Pasquali; S Vaño; L Ríos-Buceta; J Malvehy; R Taberner; L Ferrándiz
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2017-10-31

4.  Urban Teledermatology: Concept, Advantages, and Disadvantages.

Authors:  G Romero-Aguilera; L Ferrandiz; D Moreno-Ramírez
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2018-04-09

5.  Outpatient Dermatological Diagnoses in Spain: Results From the National DIADERM Random Sampling Project.

Authors:  A Buendía-Eisman; S Arias-Santiago; A Molina-Leyva; Y Gilaberte; P Fernández-Crehuet; H Husein-ElAhmed; A Viera-Ramírez; P Fernández-Peñas; R Taberner; M Á Descalzo; I García-Doval
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2018-03-20

6.  Teledermatology by WhatsApp in Valencia: Characteristics of Remote Consultation and Its Emotional Impact on the Dermatologist.

Authors:  M Gimeno-Vicente; A Alfaro-Rubio; E Gimeno-Carpio
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2020-05-11

7.  Teledermatology in the wake of COVID-19: Advantages and challenges to continued care in a time of disarray.

Authors:  Rohit Gupta; Marina K Ibraheim; Hung Q Doan
Journal:  J Am Acad Dermatol       Date:  2020-04-22       Impact factor: 11.527

8.  Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation.

Authors:  Ivy Lee; Carrie Kovarik; Trilokraj Tejasvi; Michelle Pizarro; Jules B Lipoff
Journal:  J Am Acad Dermatol       Date:  2020-03-27       Impact factor: 11.527

9.  Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy.

Authors:  Alexandra Maria Giovanna Brunasso; Cesare Massone
Journal:  Dermatol Ther       Date:  2020-06-22       Impact factor: 3.858

10.  Telemedicine Practice: Review of the Current Ethical and Legal Challenges.

Authors:  Giulio Nittari; Ravjyot Khuman; Simone Baldoni; Graziano Pallotta; Gopi Battineni; Ascanio Sirignano; Francesco Amenta; Giovanna Ricci
Journal:  Telemed J E Health       Date:  2020-02-12       Impact factor: 3.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.